Zhang Kui, Bai Peng, Dai Hao, Deng Zhenhua
Department of Forensic Pathology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, People's Republic of China.
Department of Forensic Pathology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, People's Republic of China.
Prim Care Diabetes. 2021 Feb;15(1):52-58. doi: 10.1016/j.pcd.2020.06.001. Epub 2020 Jun 27.
We carried out this meta-analysis on all published studies to estimate the overall cancer risk of the use of metformin in T2DM patients.
We searched the PubMed, Embase and CNKI databases for all articles within a range of published years from 2007 to 2019 on the association between the use of metformin and cancer risk in T2DM patients. The odds ratio (OR) corresponding to the 95% confidence interval (95% CI) was used to assess the association using a random-effect meta-analysis.
Finally, 67 studies met the inclusion criteria for this study, with 10,695,875 T2DM patients and 145,108 cancer cases. Overall, For T2DM patients of ever vs. never metformin users, there was statistical evidence of significantly decreased cancer risk was found to be associated with ever metformin users (OR=0.70, 95% CI=0.65-0.76). Considering T2DM may be a specific and independent risk factor for various forms of cancer, due to its particular metabolic characteristics of glucose intolerance and hyperinsulinemia, we performed a comparison to estimate the effects of metformin on cancer risk with other anti-diabetes medications (ADMs), our results found significantly decreased cancer risk to be associated with the use of metformin (OR=0.80, 95% CI=0.73-0.87).
Our meta-analysis indicated that metformin may be a independent protective factor for cancer risk in T2DM patients.
我们对所有已发表的研究进行了这项荟萃分析，以评估2型糖尿病（T2DM）患者使用二甲双胍的总体癌症风险。
我们在PubMed、Embase和中国知网数据库中搜索了2007年至2019年发表的所有关于T2DM患者使用二甲双胍与癌症风险之间关联的文章。采用随机效应荟萃分析，用对应95%置信区间（95%CI）的比值比（OR）来评估这种关联。
最终，67项研究符合本研究的纳入标准，涉及10695875例T2DM患者和145108例癌症病例。总体而言，对于曾使用与未使用二甲双胍的T2DM患者，有统计学证据表明曾使用二甲双胍的患者癌症风险显著降低（OR=0.70，95%CI=0.65-0.76）。鉴于T2DM可能因其葡萄糖不耐受和高胰岛素血症的特殊代谢特征而成为各种癌症的特定独立风险因素，我们进行了一项比较，以评估二甲双胍与其他抗糖尿病药物（ADM）对癌症风险的影响，结果发现使用二甲双胍与癌症风险显著降低相关（OR=0.80，95%CI=0.73-0.87）。
我们的荟萃分析表明，二甲双胍可能是T2DM患者癌症风险的独立保护因素。
